生物科技初创公司TIBEAY Biosciences筹集3500万欧元融资，用于Ronopterin在创伤性脑损伤中的3b期临床试验-动脉网

Biotech start-up TIBEAY secures 35 million euros for first therapy for severe traumatic brain injury

D-Pharm 等信源发布 2026-04-16 13:46



可切换为仅中文







MIG Capital announced its participation in a

MIG资本宣布参与了

financing

融资

of TIBEAY Biosciences B.V., Nijmegen, Netherlands. MIG Funds 4, 6, 12, 17 are currently providing EUR 2.5 million to the start-up and intend to increase their investment in the future. TIBEAY is a clinical biotechnology company focusing on innovative therapies for acute

荷兰奈梅亨TIBEAY生物科学公司。MIG基金4、6、12、17目前正在为这家初创公司提供250万欧元，并计划未来增加投资。TIBEAY是一家临床生物技术公司，专注于急性病症的创新疗法。

neurological diseases

神经系统疾病

. The successful completion of the 35 million euro financing round was led by Munich-based Athos KG. The Dutch investors Meneldor and Oost NL are also involved.

这笔3500万欧元的融资轮成功完成，由总部位于慕尼黑的Athos KG领投，荷兰投资者Meneldor和Oost NL也参与其中。

TIBEAY is developing a drug for a previously unsolved challenge. Traumatic brain injury (TBI), for example as a result of serious accidents, is a very common cause of death worldwide and can lead to long-term disabilities. It is estimated that around 50 million new cases occur worldwide every year, of which around ten percent are classified as serious.

TIBEAY 正在开发一种针对以往未解决的挑战的药物。创伤性脑损伤（TBI），例如由于严重事故导致的损伤，是全球范围内非常常见的死亡原因，并可能导致长期残疾。据估计，全球每年约有 5000 万新发病例，其中约百分之十被归类为严重病例。

In Europe alone, there are around 1.5 million annual hospital admissions. For those affected and their families, this often means lifelong restrictions with significantly impaired quality of life and independence. To date, there are no approved pharmacological therapies that specifically address the progressive damage caused by severe TBI..

在欧洲，每年约有150万例住院患者。对于受影响者及其家人来说，这通常意味着终身受限，生活质量和独立性显著下降。迄今为止，尚无获批的药物疗法能够专门应对严重创伤性脑损伤（TBI）引起的渐进性损害。

While the primary damage is caused directly by the trauma, a significant proportion of the neurological sequelae are caused by secondary processes, in particular by the formation of cell-damaging reactive oxygen and nitrogen radicals.

虽然主要损害是由创伤直接造成的，但很大一部分神经后遗症是由继发过程引起的，特别是由细胞损伤性的活性氧和氮自由基的形成所致。

With the drug Ronopterin, TIBEAY is pursuing the approach of selectively inhibiting inducible nitric oxide synthase (iNOS). After a brain injury, iNOS is increasingly expressed and contributes to the formation of neurotoxic oxygen and nitrogen radicals. Through this selective inhibition of iNOS, ronopterin reduces secondary brain damage and improves the neurological condition and thus the quality of life of patients with severe TBI..

通过药物罗诺普特林，TIBEAY 采取了选择性抑制诱导型一氧化氮合酶 (iNOS) 的方法。脑损伤后，iNOS 的表达增加，并导致神经毒性氧和氮自由基的形成。通过对 iNOS 的选择性抑制，罗诺普特林减少了继发性脑损伤，改善了神经功能状况，从而提高了重度 TBI 患者的生活质量。

The funds now raised will be used for a planned phase 3b study. This builds on the clinical findings to date and will include patients with acute severe TBI in several European countries. The study design has been further optimized based on previous clinical findings and will focus on early treatment initiation and targeted patient selection.

目前筹集的资金将用于计划中的第三阶段b研究。这项研究基于迄今为止的临床发现，将在几个欧洲国家包括急性严重TBI患者。根据之前的临床发现，研究设计得到了进一步优化，并将专注于早期治疗启动和有针对性的患者选择。

The pivotal phase 3b study is the basis for the submission of the marketing authorization application to the European Medicines Agency (EMA)..

关键的 3b 期研究是向欧洲药品管理局 (EMA) 提交上市许可申请的基础。

In addition to the clinical development of the first-in-class active ingredient Ronopterin, the funds will also be used for the manufacture of the investigational product, securing the supply chain and for regulatory and operational preparations with a view to possible approval in Europe. In addition, selected preparatory activities will be initiated to support future market access..

除了同类首创活性成分罗诺替林的临床开发外，这笔资金还将用于生产研究药物、确保供应链以及为可能在欧洲获得批准进行监管和操作上的准备。此外，还将启动选定的预备活动以支持未来的市场准入。

What makes TIBEAY particularly attractive for MIG Capital is the promising potential of ronopterin. The active ingredient makes it possible to set a new standard in a previously unoccupied, clearly definable market segment and is therefore also highly relevant for specialized pharmaceutical and commercialization partners..

让TIBEAY对MIG Capital特别有吸引力的是罗诺替林（ronopterin）的良好潜力。这种活性成分使得在之前未被占领的、明确可定义的细分市场中树立新标准成为可能，因此对专业的医药和商业化合作伙伴也具有高度的相关性。

Andreas Kastenbauer, Partner at MIG Capital, comments: 'With TIBEAY, we are investing in a promising therapeutic approach. Ronopterin addresses a biological signaling pathway whose medical relevance was already recognized with the Nobel Prize for Medicine in 1998. As an investor, we want to help close a previously unmet therapeutic gap.'.

MIG资本的合伙人安德烈亚斯·卡斯滕鲍尔评论道：“通过投资TIBEAY，我们正在支持一种富有前景的治疗方法。罗诺普特林针对的是一条生物信号通路，其医学重要性早在1998年就已因诺贝尔医学奖而得到认可。作为投资者，我们希望帮助填补之前未满足的治疗空白。”

Prof. Dr. John Stover, CMO of TIBEAY, comments: 'We are on the verge of a medical breakthrough: Ronopterin could for the first time provide an effective therapy for patients with severe traumatic brain injury - a patient group for which there is currently no approved treatment. Ronopterin has the potential to improve the neuropsychological condition and quality of life of those affected'..

TIBEAY公司首席医疗官约翰·斯托弗教授评论道：“我们正处于医学突破的边缘：罗诺普特林首次为严重创伤性脑损伤患者提供了有效的治疗方法——目前这一患者群体尚无获批的治疗方案。罗诺普特林有潜力改善受影响者的神经心理状况和生活质量。”

Paul Lelieveld, founder and Managing Partner of Meneldor, adds: 'We are very pleased to be working with Athos, MIG Capital and Oost NL on a significant treatment for traumatic brain injury. We are grateful for the trust and the work that the management and all parties involved have done so far.'

保罗·勒利维尔德，Meneldor的创始人兼管理合伙人补充说：“我们很高兴能与Athos、MIG资本和Oost NL合作，为创伤性脑损伤提供重要的治疗方案。我们感谢管理层和所有相关方迄今为止所给予的信任和付出的努力。”

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar.

注意：本文已通过计算机系统翻译，未经人工干预。LUMITOS 提供这些自动翻译，以呈现更广泛的当前新闻。由于本文是通过自动翻译翻译的，因此可能会包含词汇、句法或语法方面的错误。

The original article in German can be found .

原文为德语，可以找到。

here

这里

。

https://www.bionity.com/en/news/1188505/biotech-start-up-tibeay-secures-35-million-euros-for-first-therapy-for-severe-traumatic-brain-injury.html

https://www.bionity.com/en/news/1188505/biotech-start-up-tibeay-secures-35-million-euros-for-first-therapy-for-severe-traumatic-brain-injury.html生物技术初创公司Tibeay为其首个重度创伤性脑损伤疗法获得3500万欧元资金。

Traumatic brain injury: designer molecule supports brain repair

创伤性脑损伤：设计分子支持大脑修复

International research team has discovered how repair after a brain injury can be improved by influencing immune cells

国际研究团队发现如何通过影响免疫细胞来改善脑损伤后的修复。

Read news

读新闻